Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform … Read more
Champions Oncology Inc (CSBR) - Net Assets
Latest net assets as of October 2025: $4.23 Million USD
Based on the latest financial reports, Champions Oncology Inc (CSBR) has net assets worth $4.23 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.16 Million) and total liabilities ($25.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.23 Million |
| % of Total Assets | 14.03% |
| Annual Growth Rate | 7.78% |
| 5-Year Change | -49.22% |
| 10-Year Change | 1484.87% |
| Growth Volatility | 6073.2 |
Champions Oncology Inc - Net Assets Trend (1996–2025)
This chart illustrates how Champions Oncology Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Champions Oncology Inc (1996–2025)
The table below shows the annual net assets of Champions Oncology Inc from 1996 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | $3.77 Million | +298.21% |
| 2024-04-30 | $-1.90 Million | -141.05% |
| 2023-04-30 | $4.64 Million | -49.03% |
| 2022-04-30 | $9.10 Million | +22.46% |
| 2021-04-30 | $7.43 Million | +45.68% |
| 2020-04-30 | $5.10 Million | +127.84% |
| 2019-04-30 | $2.24 Million | +9052.00% |
| 2018-04-30 | $-25.00K | -106.25% |
| 2017-04-30 | $400.00K | +68.07% |
| 2016-04-30 | $238.00K | -97.05% |
| 2015-04-30 | $8.06 Million | +152.08% |
| 2014-04-30 | $3.20 Million | -57.96% |
| 2013-04-30 | $7.60 Million | +244.07% |
| 2012-04-30 | $-5.28 Million | -27878.95% |
| 2011-04-30 | $19.00K | -98.80% |
| 2010-04-30 | $1.58 Million | -17.69% |
| 2009-04-30 | $1.92 Million | -47.33% |
| 2008-04-30 | $3.64 Million | +1493.34% |
| 2007-04-30 | $-261.06K | +61.06% |
| 2006-04-30 | $-670.51K | -82.80% |
| 2005-04-30 | $-366.80K | -295.66% |
| 2004-04-30 | $-92.70K | +55.80% |
| 2003-04-30 | $-209.75K | -4090.79% |
| 2002-04-30 | $-5.00K | -103.31% |
| 2001-04-30 | $151.06K | -83.06% |
| 2000-04-30 | $891.69K | +0.19% |
| 1999-04-30 | $890.00K | -5.32% |
| 1998-04-30 | $940.00K | +44.62% |
| 1997-04-30 | $650.00K | +51.16% |
| 1996-04-30 | $430.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Champions Oncology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7445200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.00K | 0.37% |
| Other Components | $83.65 Million | 2217.66% |
| Total Equity | $3.77 Million | 100.00% |
Champions Oncology Inc Competitors by Market Cap
The table below lists competitors of Champions Oncology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SaverOne 2014 Ltd. Warrant
NASDAQ:SVREW
|
$32.17 Million |
|
Bragg Gaming Group Inc
NASDAQ:BRAG
|
$32.17 Million |
|
FIH Mobile Limited
PINK:FXCNF
|
$32.17 Million |
|
4BASEBIO PLC EO 1
F:88Q
|
$32.17 Million |
|
Miko NV
BR:MIKO
|
$32.15 Million |
|
China Tianrui Group Cement Company Limited
F:T18
|
$32.13 Million |
|
PT Citra Tubindo Tbk
JK:CTBN
|
$32.13 Million |
|
Senko Co. Ltd
KQ:347000
|
$32.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Champions Oncology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,903,000 to 3,772,000, a change of 5,675,000.
- Net income of 4,701,000 contributed positively to equity growth.
- Other factors increased equity by 974,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.70 Million | +124.63% |
| Other Changes | $974.00K | +25.82% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Champions Oncology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 23.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 9.44x to 23.45x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-04-30 | $0.66 | $6.20 | x |
| 1997-04-30 | $0.88 | $6.20 | x |
| 1998-04-30 | $1.27 | $6.20 | x |
| 1999-04-30 | $1.25 | $6.20 | x |
| 2000-04-30 | $1.26 | $6.20 | x |
| 2001-04-30 | $0.21 | $6.20 | x |
| 2002-04-30 | $-0.01 | $6.20 | x |
| 2003-04-30 | $-0.30 | $6.20 | x |
| 2004-04-30 | $-0.13 | $6.20 | x |
| 2005-04-30 | $-0.33 | $6.20 | x |
| 2006-04-30 | $-0.48 | $6.20 | x |
| 2007-04-30 | $-0.15 | $6.20 | x |
| 2008-04-30 | $1.39 | $6.20 | x |
| 2009-04-30 | $0.69 | $6.20 | x |
| 2010-04-30 | $0.56 | $6.20 | x |
| 2011-04-30 | $0.01 | $6.20 | x |
| 2012-04-30 | $-1.35 | $6.20 | x |
| 2013-04-30 | $2.56 | $6.20 | x |
| 2014-04-30 | $0.57 | $6.20 | x |
| 2015-04-30 | $0.93 | $6.20 | x |
| 2016-04-30 | $0.03 | $6.20 | x |
| 2017-04-30 | $0.04 | $6.20 | x |
| 2018-04-30 | $0.00 | $6.20 | x |
| 2019-04-30 | $0.16 | $6.20 | x |
| 2020-04-30 | $0.43 | $6.20 | x |
| 2021-04-30 | $0.51 | $6.20 | x |
| 2022-04-30 | $0.64 | $6.20 | x |
| 2023-04-30 | $0.34 | $6.20 | x |
| 2024-04-30 | $-0.14 | $6.20 | x |
| 2025-04-30 | $0.26 | $6.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Champions Oncology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 124.63%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.26%
- • Asset Turnover: 1.76x
- • Equity Multiplier: 8.57x
- Recent ROE (124.63%) is above the historical average (-909.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 11.36% | 2.34% | 2.89x | 1.68x | $6.00K |
| 1997 | 44.62% | 13.43% | 2.16x | 1.54x | $225.00K |
| 1998 | 38.30% | 15.45% | 1.75x | 1.41x | $266.00K |
| 1999 | 2.25% | 0.91% | 1.63x | 1.52x | $-69.00K |
| 2000 | 5.78% | 2.37% | 1.54x | 1.59x | $-37.66K |
| 2001 | -448.10% | -30.62% | 2.52x | 5.80x | $-691.99K |
| 2002 | 0.00% | -6.92% | 2.71x | 0.00x | $-146.81K |
| 2003 | 0.00% | -7.28% | 4.12x | 0.00x | $-125.02K |
| 2004 | 0.00% | -5.39% | 5.10x | 0.00x | $-98.42K |
| 2005 | 0.00% | -13.72% | 6.74x | 0.00x | $-209.86K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-236.67K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-143.95K |
| 2008 | -11.30% | -29.36% | 0.30x | 1.28x | $-774.75K |
| 2009 | -117.01% | -60.43% | 0.80x | 2.41x | $-2.43 Million |
| 2010 | -185.35% | -59.74% | 1.24x | 2.49x | $-3.08 Million |
| 2011 | -20010.53% | -55.25% | 0.54x | 665.79x | $-3.80 Million |
| 2012 | 0.00% | -121.15% | 1.03x | 0.00x | $-8.13 Million |
| 2013 | -83.25% | -76.05% | 0.71x | 1.54x | $-7.09 Million |
| 2014 | -231.65% | -64.12% | 1.30x | 2.77x | $-7.73 Million |
| 2015 | -163.05% | -148.26% | 0.74x | 1.49x | $-13.95 Million |
| 2016 | -4389.08% | -93.42% | 1.94x | 24.27x | $-10.47 Million |
| 2017 | -1721.00% | -44.67% | 1.92x | 20.03x | $-6.92 Million |
| 2018 | 0.00% | -7.29% | 2.51x | 0.00x | $-1.47 Million |
| 2019 | 5.72% | 0.47% | 2.40x | 5.03x | $-95.80K |
| 2020 | -41.05% | -6.52% | 1.55x | 4.07x | $-2.60 Million |
| 2021 | 4.87% | 0.88% | 1.49x | 3.71x | $-380.80K |
| 2022 | 6.02% | 1.12% | 1.39x | 3.89x | $-361.60K |
| 2023 | -115.08% | -9.90% | 1.57x | 7.40x | $-5.80 Million |
| 2024 | 0.00% | -14.51% | 1.92x | 0.00x | $-7.09 Million |
| 2025 | 124.63% | 8.26% | 1.76x | 8.57x | $4.32 Million |
Industry Comparison
This section compares Champions Oncology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Champions Oncology Inc (CSBR) | $4.23 Million | 11.36% | 6.13x | $32.16 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |